RIGL Q4 2020 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$541M

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$18M+19.8% YoY

Gross Profit

$18M98.3% margin

Operating Income

-$19M-102.0% margin

Net Income

-$19M-104.3% margin

EPS (Diluted)

$-1.10

QoQ Revenue Growth

+0.3%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$16M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$110M

Total Liabilities

$76M

Stockholders' Equity

$34M

Cash & Equivalents

$30M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$18M	$15M	+19.8%
Gross Profit	$18M	$15M	+19.1%
Operating Income	-$19M	-$17M	-8.6%
Net Income	-$19M	-$17M	-11.8%

Revenue Segments

Gross Product

$22M64%

Product

$18M51%

Contract Revenues From Collaborations

$697,0002%

Research And Development Services And Others

$197,0001%

License

-$2M-5%

Discounts And Allowances

-$5M-13%